PGC-1α in osteoarthritic chondrocytes: From mechanism to target of action

Frontiers in Pharmacology

Pharmacology

Yang Xia¹  Haochen Wang²  Yingliang Wei²  Jianbang Su²  Minghao Yu² 

[1]Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China

[2]Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, China

关键词: osteoarthritis;    chondrocyte;    PGC- 1α;    metabolism;    apoptosis;    mitochondria;   

DOI  :  10.3389/fphar.2023.1169019

 received in 2023-02-18, accepted in 2023-03-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Osteoarthritis (OA) is one of the most common degenerative joint diseases, often involving the entire joint. The degeneration of articular cartilage is an important feature of OA, and there is growing evidence that the mitochondrial biogenesis master regulator peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) exert a chondroprotective effect. PGC-1α delays the development and progression of OA by affecting mitochondrial biogenesis, oxidative stress, mitophagy and mitochondrial DNA (mtDNA) replication in chondrocytes. In addition, PGC-1α can regulate the metabolic abnormalities of OA chondrocytes and inhibit chondrocyte apoptosis. In this paper, we review the regulatory mechanisms of PGC-1α and its effects on OA chondrocytes, and introduce potential drugs and novel nanohybrid for the treatment of OA which act by affecting the activity of PGC-1α. This information will help to further elucidate the pathogenesis of OA and provide new ideas for the development of therapeutic strategies for OA.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Su, Yu, Xia and Wei.